Abstract:Myeloid-derived suppressor cells (MDSCs) are a heterogeneous family of myeloid cells that suppress T cell immunity in tumor-bearing hosts. In patients with colon cancer, MDSCs have recently been described as Lin(-/low)HLA-DR(-)CD11b(+)CD33(+) cells correlating with cancer stage, metastasis and chemotherapy response. To learn in more detail the dynamic change and clinical relevance of circulating and tumor-infiltrating Lin(-)/lowHLA-DR(-)CD11b(+)CD33(+) MDSC in colorectal cancer, we harvested the blood from 64 patients with varying stage of colorectal cancer and tumor and matched paraneoplastic tissues from 5 patients with advanced colorectal cancer, subjected them to multicolor flow cytometric analysis of percentage, absolute number and phenotype of MDSC and finally characterized their immunosuppressive functions. Our results demonstrate that peripheral blood from colorectal cancer patients contains markedly increased percentage and absolute number of Lin(-/low)HLA-DR(-)CD11b(+)CD33(+) MDSCs compared with healthy individuals, and this increase is closely correlated with clinical cancer stage and tumor metastasis but not primary tumor size and serum concentrations of cancer biomarker. A similar increase of MDSCs was also observed in the tumor tissues. Phenotyping MDSCs shows that they express high CD13 and CD39, low CD115, CD117, CD124 and PD-L1, and devoid of CD14, CD15 and CD66b, reminiscent of precursor myeloid cells. MDSCs from cancer patients but not healthy donors have the immunosuppressive activity and were able to inhibit in vitro autologous T-cell proliferation. Collectively, this study substantiates the presence of increased immunosuppressive circulating and tumor-resident Lin(-/low)HLA-DR(-)CD11b(+)C33(+) MDSCs in patients with colorectal cancers correlating with cancer stage and metastasis, and suggests that pharmacologic blockade of MDSCs should be considered in future clinical trials.

Mechanisms of myeloid-derived suppressor cell-mediated immunosuppression in colorectal cancer and related therapies

Myeloid-Derived Suppressor Cells: A New and Pivotal Player in Colorectal Cancer Progression

Myeloid‑derived suppressor cells: Key immunosuppressive regulators and therapeutic targets in colorectal cancer (Review)

Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies

Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer

Myeloid-Derived Suppressor Cells in Tumors: From Mechanisms to Antigen Specificity and Microenvironmental Regulation

Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion

Immunotherapy of targeting MDSCs in tumor microenvironment

Myeloid-derived suppressor cells: Key immunosuppressive regulators and therapeutic targets in cancer

Targeting Myeloid-Derived Suppressor Cells in Cancer Immunotherapy

Targeted modulation of myeloid-derived suppressor cells in the tumor microenvironment: Implications for cancer therapy

Circulating And Tumor-Infiltrating Myeloid-Derived Suppressor Cells In Patients With Colorectal Carcinoma

Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy

The role of myeloid‐derived suppressor cells in gastrointestinal cancer

Myeloid-derived suppressor cells in cancer and cancer therapy

Tumor-induced Myeloid-Derived Suppressor Cells Promote Tumor Progression Through Oxidative Metabolism in Human Colorectal Cancer

Myeloid-Derived Suppressor Cells: Roles In The Tumor Microenvironment And Tumor Radiotherapy

Myeloid-derived Suppressor Cells:Mechanisms of Immune Suppression and Advancements in Anti-Tumor Immunity Therapy

Highlights on Mechanisms of Drugs Targeting MDSCs: Providing a Novel Perspective on Cancer Treatment

Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy

Reprogramming immunosuppressive myeloid cells by activated T cells promotes the response to anti-PD-1 therapy in colorectal cancer